Clinical trial
Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients
NCT00037531 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00037531 |
|---|---|
| Title | Study Evaluating Sirolimus (Rapamune™) in Solid Organ Transplant Recipients |
| Official title | An Open-label Extension Study of the Safety of Long-term Administration of Sirolimus (Rapamune™) in Solid Organ Transplant Recipients |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Graft vs Host Disease, Kidney Transplantation |
| Intervention type | Drug |
| Interventions | Sirolimus (RAPAMUNE) |
| Enrollment | 769 |
| Primary completion | Aug 1, 2004 |
| Completion | Aug 1, 2004 |
| First posted | May 20, 2002 |
| Last update posted | Aug 18, 2009 |
| Countries | Canada, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: